$IMNN News

Imunon IMNN Q4 2025 Earnings Transcript

IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27

Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...

Imunon (IMNN) Q1 2026 Earnings Transcript

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Imunon Reports Q1 2026 Results: Full Earnings Call Transcript

Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10

Imunon, Inc. Q4 2025 Earnings Call Summary

IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule

Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management

IMUNON INC (NASDAQ:IMNN) Reports Q4 2025 Results with Focus on Phase 3 Progress for IMNN-001

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation

IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC